Francais
info@saveyourskin.ca

clinical trials

ASCO 2023 Data Report

Earlier this summer, Save Your Skin was fortunate enough to attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, in order to hear the latest data from melanoma clinical trials. We are pleased to present the highlights from these exciting studies in our annual ASCO report, which this year includes data from trials relating to melanoma, non-melanoma skin cancers (NMSC), and uveal (ocular) melanoma. Please keep in mind that ASCO is an international association, and therefore studies outlined in this report are not exclusive to Canada.

This report includes:

  • Trial updates related to melanoma, non-melanoma skin cancers (NMSC), and uveal (ocular) melanoma
  • A glossary of abbreviations used in the report
  • A selection of melanoma-related news articles from the summer for supplemental reading

You can read the report here or by clicking on the cover image below. Thank you for reading!

Read more

Understanding the Drug Approval Process: From Clinical Trials to Public Reimbursement

This webinar will discuss the drug approval process starting from clinical trials to public reimbursement.

Our expert speakers will explain how clinical trials are designed, how to find and access clinical trials in Canada, and how to determine if they are right for you.

Attendees will learn how drugs get approved in Canada and who the stakeholders involved are, following the process from clinical trials and efficacy reviews to patient submissions and Health Canada approvals, and finally, provincial reimbursement.

Moderated by Kathy Barnard, Founder/President of Save Your Skin Foundation, Stage IV Melanoma Survivor

START TIME:
8PM EST | 5PM PST | 6PM MST | 9:30PM NST | 9PM AST

Click here for more information

Read more

Understanding the Drug Approval Process: From Clinical Trials to Public Reimbursement

Thank you so much to all who attended our webinar!

If you weren’t able to join us live, you can watch the recording of the symposium on our Youtube channel.

Date: 
April 19, 2023

Start Time:
Starts: 8pm EST | 5pm PST | 6pm MST | 9:30pm NST | 9pm AST

This webinar will discuss the drug approval process starting from clinical trials to public reimbursement.

Our expert speakers will explain how clinical trials are designed, how to find and access clinical trials in Canada, and how to determine if they are right for you.

Attendees will learn how drugs get approved in Canada and who the stakeholders involved are, following the process from clinical trials and efficacy reviews to patient submissions and Health Canada approvals, and finally, provincial reimbursement.

Moderated by Kathy Barnard, Founder/President of Save Your Skin Foundation, Stage IV Melanoma Survivor

Our Key Presenters:

  • Dawn Richards, PhD, Director of Patient and Public Engagement at Clinical Trials Ontario, Founder of Five02Labs
  • Louise Binder, Lawyer, Senior Health Policy Expert at Save Your Skin Foundation

ADDITIONAL INFORMATION

Kathleen Barnard is Founder and President of Save Your Skin Foundation (SYSF), a national not-for-profit group dedicated to the prevention of non-melanoma skin cancers, melanoma, and ocular melanoma. In 2003, Kathy was diagnosed with stage 4 malignant melanoma. By the establishment of SYSF in 2006, her cancer had spread to her vital organs and her treatment options were limited. Fortunately, one of her sons discovered an immunotherapy trial treatment taking place in Alberta, Canada; this trial would save Kathy’s life. While her cancer treatments have finished, the battle with melanoma is not over for Barnard. Kathy prioritizes patient care and support. Kathy was a key player in federal tanning bed legislation for Canada’s Youth, and is the recipient of the British Columbia Community Achievement Award for her leadership in addressing and raising awareness around skin cancer issues. Additionally, Kathy is on the Conference Board of Canada advisory committee for Value of Oncology Innovation in Canada.

Louise Binder is a lawyer and health advocate who has been involved in informing the development of health policy and systemic treatment access practices from a patient perspective for more than 20 years. She started her work in this area in the HIV community in the early 1990s after her own diagnosis and before effective treatments were available for HIV.

She co-founded the Canadian Treatment Action Council (CTAC) in 1996, which successfully ensured access to treatments and quality care for people living with HIV by working with the federal and provincial governments and other relevant stakeholders to enhance drug review and approval systems, pricing policies and access to liver transplants for this community. She wrote a paper on universal drug coverage a decade ago while chair of CTAC.

She had a special interest in women’s issues, chairing the Ontario women’s organization Voice of Positive Women for more than a decade, and has been involved in these issues internationally as well. Two years ago, Louise began similar work in the cancer area and is presently a Health Policy Consultant with Save Your Skin Foundation. She has been recognized by many organizations for her work, including receiving an Honorary Doctorate of Laws from her alma mater, Queen’s Law School; the Order of Ontario from the Province of Ontario; and two Queen Elizabeth II medals.

Dawn Richards, PhD, is the founder of Five02 Labs Inc., and Director of Patient and Public Engagement at Clinical Trials Ontario. With a PhD (Analytical Chemistry) from the University of Alberta, and experience in a variety of roles during the past 20 years, it is her diagnosis with rheumatoid arthritis in 2006 that started her journey to combine her passion for science with making the most of her diagnosis. In her role at CTO, Dawn is charged with executing on CTO’s strategic pillar of patient and public engagement.

Read more

WEBINAR: Latest news on melanoma/skin cancer/ocular melanoma from ASCO 2022

(le français suit)

Don’t miss our webinar with Dr. Marcus Butler, the Medical Oncology Disease Site Lead for Melanoma/Skin Oncology at Princess Margaret Cancer Centre and Assistant Professor of Medicine at the University of Toronto. He is also the Clinical Director for the Immune Monitoring Team at the Princess Margaret where he focuses on the immunologic impact of anti-cancer immunotherapies.

This webinar reviews late breaking news, key takeaways, clinical data and other updates presented at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, in June 2022.

Dr. Butler shares his key insights into what the landscape of melanoma, non-melanoma skin cancers, and ocular melanoma treatment looks like for the near future in Canada.

Click HERE to view the recording

 

WEBINAIRE : Mise à jour sur le mélanome/cancer de la peau/mélanome oculaire de l’ASCO 2022

Regardez l’enregistrement du webinaire avec le Dr Marcus Butler, responsable du site d’oncologie médicale pour le mélanome et l’oncologie de la peau au Princess Margaret Cancer Centre et professeur adjoint de médecine à l’Université de Toronto. Il est également le directeur clinique de l’équipe de surveillance immunitaire du Princess Margaret, où il se concentre sur l’impact immunologique des immunothérapies anticancéreuses.

Ce webinaire a passé en revue les dernières nouvelles, les points essentiels, les données cliniques et d’autres mises à jour présentées lors de l’assemblée annuelle de l’American Society of Clinical Oncology (ASCO) qui a eu lieu à Chicago, en Illinois, en juin 2022.

Le Dr Butler a partagé ses idées clés sur ce à quoi ressemble le paysage du traitement du mélanome, des cancers de la peau autres que le mélanome et du mélanome oculaire dans un avenir proche au Canada.

Cliquez ici pour le webinaire

Read more

ASCO 2021 Conference Report by SYSF

The 2021 American Society of Clinical Oncology Annual Meeting took place from June 4-8, 2021. Given the COVID-19 pandemic, the convention was conducted entirely online. This event brings together over thirty thousand oncologists, pharmaceutical representatives, and patient advocates from across the world and across cancer types for five days of networking, learning, and presenting new research. Every year, Save Your Skin Foundation puts together a report of the panels regarding innovative treatments in the melanoma sphere. In this report are detailed recollections of these panels, categorized by topic. All information offered in this report is the intellectual property of the presenter and their team, as cited by the report.

Click here to read the report!

 

Every year, melanoma and uveal melanoma become more widely covered by clinical trials. While the continued innovation of treatment for these cancers is exciting, it means that we were unable to include every presentation and abstract related to melanoma, uveal melanoma, and non-melanoma skin cancers. Therefore, abstracts and presentations that provide updates on safety profiles of past studies and abstracts that do not produce promising clinical results have been excluded. We have also excluded abstracts which, at the time of the meeting, did not have confirmed data.

The informational resources cited in this report are a combination of the transcripts and slides from the ASCO meeting library. All images are courtesy of the author of the respective talk. Any queries may be directed to natalie@saveyourskin.ca

If you are interested in more information from the ASCO 2021 annual meeting, Save Your Skin Foundations is pleased to offer a Post-ASCO 2021 Update with Dr Omid Hamid video concentrated on melanoma, non-melanoma skin cancers, and ocular melanoma. Click HERE to view the recording on youTube

 

Read more

Post-ESMO Webinar with Dr. Dummer: Skin Cancer News 2020

Webinar Recording Available! Click HERE

Presented by Professor Reinhard Dummer, Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland, this webinar reviews late breaking news, key takeaways, clinical data and other updates presented at the European Society for Medical Oncology (ESMO) Virtual Congress Annual Meeting September-October 2020.  Dr. Dummer shares his key insights into what the landscape of melanoma and non-melanoma skin cancer treatment looks like for the near future.  Watch until the end to see Dr. Dummer and Kathy Barnard discuss hope and survivorship in melanoma skin cancer.

***

Prof. Reinhard Dummer, MD
Vice-Chairman, Department of Dermatology
University Hospital of Zürich, Switzerland

Professor Reinhard Dummer is Professor of the University of Zurich and Vice-Chairman of the Department of Dermatology in the University Hospital of Zürich, Switzerland and is a key thought leader in worldwide cutaneous oncology. Currently he is heading of the Skin Cancer Unit and the Clinical Trial Unit of the Department of Dermatology. Professor Dummer began his medical education in haematology and oncology before successfully completing his dermatology residency in Würzburg, Germany, and Zürich in 1992.

He is Board Certified in allergology, clinical immunology, dermatology and dermatopathology.

Professor Dummer’s principal research interests are molecular biology, immunology and immunotherapy of cutaneous malignancies, including cutaneous lymphomas and melanomas. He has published more than 741 papers with a cumulative impact factor of more than 6372. He w as past-president of the Melanoma Project Group of the Swiss Institute for Applied Cancer Research since 1999 -2016, is a member of German National Academy of Sciences (Leopoldina) and is past board member of the Society for Melanoma Research and past President of the International Society for Cutaneous Lymphomas.

He is a founding and board member of the European Association of Dermato-Oncology (EADO), ESMO, URPP and past President of the European Society for Dermatological Research (ESDR).

In the last 20 years, he has developed a leading skin cancer center. This center offers best medical care, a network of clinical trials reaching from phase I to phase III. His contributions are acknowledge in many publications in outstanding journals such as New England Journal of Medicine, Lancet, Lancet Oncology, Press etc. Locally he is intensify cooperation with basic research group at the University and the federal University (ETH). This has resulted in translation work improving our understanding of cutaneous malignancies.

To view the webinar recording please CLICK HERE

 

Read more

ASCO 2020 Event Report

In 2020, the American Society of Clinical Oncology meeting was held online due to the COVID-19 pandemic. The meeting took place from May 29th-31st, with the last two days being devoted to online presentations.

This report will be dedicated to the presentations that representatives from Save Your Skin Foundation remotely attended, with a focus on melanoma, innovative treatments, and survivorship. The information in this report is sourced directly, occasionally verbatim, from ASCO presentations and abstracts. If you require more information on an abstract, the clinical trial numbers (where available) are included for your reference.

Please CLICK HERE to read or download the report.

 

Feedback or questions?  Contact us – info@saveyourskin.ca

Read more

ASCO 2019 Event Report

The 2019 American Society of Clinical Oncology Annual Meeting took place from May 31-June 4, 2019 in Chicago, Illinois. This event brings together over thirty thousand oncologists, pharmaceutical representatives, and patient advocates from across the world and across cancer types for five days of networking, learning, and presenting new research.

Every year, Save Your Skin Foundation puts together a report of the panels regarding updates on the innovative treatment of melanoma, non-melanoma skin cancer, and ocular melanoma. Included in the report are detailed recollections of these panels, in chronological order.

Please CLICK HERE to download and read the report.

 

Feedback or questions?  Contact us – info@saveyourskin.ca

Read more

SYSF Webinar: Ocular Melanoma

Ocular Melanoma – Innovative Treatments and Beyond

With Presenters:

Dr. Marcus Butler, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Dr. Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, California

Nigel Deacon, Ocular Melanoma Survivor/Patient, British Columbia, Canada

This webinar provides an update on the landscape of metastatic ocular melanoma treatment in Canada and the United States. Dr. Hamid and Dr. Butler share their knowledge of current practices and care pathways, identifying the most pressing needs for patients. They also discuss innovative treatment options such as IMCgp100, as well as clinical trials available to Canadian patients with ocular or uveal melanoma. Nigel Deacon shares his experience with this rare cancer; Kathy Barnard facilitating.

Missed the webinar? Listen to a recording of the presentation here, or watch it on our YouTube channel here.

Read more

Introducing “ForPatients” by Roche

We are happy to announce the launch of an informative website about clinical trials by another of our supporting partners.  F. Hoffmann-La Roche Ltd. has put together a website called ForPatients, which includes a search tool for finding clinical trials in various cancer indications, plus other medical conditions such as autoimmune or neurodegenerative disorders.  Anyone can search for clinical trials around the world; it is easy to navigate, and even includes an interactive map showing recruiting clinical trial locations.

ForPatients also contains detailed information about clinical trials in general, and discusses patients’ rights in and after a clinical trial. It also points out where to find published results of any given Roche trials, and it has general care tips for patients plus links to additional support resources.

We applaud Roche for this initiative, and wish patients around the world much success with this valuable new resource.  Click here to check out the new website:

ForPatients.Roche.com

 

Read more